Fractyl Health, Inc. (NASDAQ:GUTS) Insider Jay David Caplan Sells 22,346 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the sale, the insider now directly owns 153,544 shares in the company, valued at approximately $277,914.64. This represents a 12.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jay David Caplan also recently made the following trade(s):

• On Monday, November 11th, Jay David Caplan sold 64,197 shares of Fractyl Health stock. The stock was sold at an average price of $2.47, for a total value of $158,566.59.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $1.64 on Thursday. The company has a market capitalization of $78.88 million and a PE ratio of -0.13. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. Fractyl Health, Inc. has a twelve month low of $1.52 and a twelve month high of $11.55. The firm has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $2.47.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. On average, sell-side analysts forecast that Fractyl Health, Inc. will post -1.66 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley lowered their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors have recently added to or reduced their stakes in GUTS. Geode Capital Management LLC increased its stake in shares of Fractyl Health by 166.5% in the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock valued at $1,269,000 after acquiring an additional 313,335 shares in the last quarter. Conservest Capital Advisors Inc. acquired a new stake in Fractyl Health in the fourth quarter worth $132,000. State Street Corp increased its stake in Fractyl Health by 129.4% in the third quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after purchasing an additional 63,968 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Fractyl Health by 4.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after purchasing an additional 49,289 shares during the period. Finally, Barclays PLC raised its holdings in shares of Fractyl Health by 1,754.7% during the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock valued at $121,000 after purchasing an additional 45,219 shares during the period.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.